中国麻风皮肤病杂志 ›› 2017, Vol. 33 ›› Issue (8): 449-456.

• 论著 •    下一篇

Secukinumab治疗成人中重度银屑病疗效和安全性的Meta分析

李超  田怀平  唐跃年   

  1. 上海交通大学医学院附属新华医院药学部，上海，200092
  • 出版日期:2017-08-15 发布日期:2018-12-03
  • 通讯作者: 唐跃年，E-mail: tangyuenian@xinhuamed.com.cn

Efficacy and safety of secukinumab in the treatment of adults patients with moderate-severe psoriasis: a meta-analysis

LI Chao, TIAN Huaiping, TANG Yuenian.   

  1. Department of Pharmacy, Xinhua Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China
  • Online:2017-08-15 Published:2018-12-03
  • Contact: TANG Yuenian, E-mail: tangyuenian@xinhuamed.com.cn

PDF (PC)

87

摘要： 目的：评价Secukinumab治疗成人中重度银屑病的疗效和安全性。方法：计算机检索PubMed、EMBASE、Cochrane图书馆、中国知网、维普期刊数据库、万方医学数据库、中国生物医学文献数据库有关Secukinumab治疗成人中重度银屑病的随机对照试验文献，时间为数据库建库时间至2017年2月，由两名独立的研究员对纳入的文献进行质量评价，用RevMan 5.3软件进行Meta分析。结果：分析共纳入7篇文献、3474例成人中重度银屑病患者。Meta分析结果显示，300 mg Secukinumab治疗组中PASI积分下降75% 、90%和100%的患者例数和研究者全面评估（IGA）分数为0或1的患者例数高于150 mg Secukinumab治疗组及安慰剂组，差异均有统计学意义（P<0.00001）。300 mg和150 mg Secukinumab治疗组中患者不良反应发生率明显高于安慰剂组，但 300 mg Secukinumab治疗组和150 mg Secukinumab治疗组间不良反应发生率差异无统计学意义。结论：300 mg Secukinumab治疗中重度银屑病疗效明显优于150 mg Secukinumab，不良反应发生率无明显差异。

关键词: Secukinumab, 银屑病, 成人, Meta分析

Abstract: Objective: To assess the efficacy and safety of secukinumab in the treatment of adults patients with moderate-severe psoriasis. Methods: The articles of the randomized, controlled clinical trials about secukinumab in the treatment of moderate-severe psoriasis in adults were searched in PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals, Wanfang Med Online, and China Biology Medicine disc from the data base establishment to February 2017. The quality of the articles was assessed by two reviewers and meta-analysis was performed using the RevMan 5.3 software. Results: Seven articles including 3474 patients met the criteria. The results of meta-analysis showed that the number of the patients with a decrease of PASI scores up to 75%, 90% and 100% and a score of Investigator's Global Assessment (IGA) of 0 or 1 in 300 mg secukinumab group was more than those treated with 150 mg secukinumab and placebo (P＜0.00001). The adverse reaction in the patients treated with 300 mg and 150 mg secukinumab was higher than those treated with placebo (P＜0.05). However, the difference in adverse reaction was not significant between the patients treated with 300 mg and 150 mg secukinumab. Conclusion: 300 mg secukinumab is more effective in the treatment of moderate-severe psoriasis than 150 mg and there is no significant difference in adverse reaction between the two groups.

Key words: secukinumab, psoriasis, adult, meta-analysis